1. Home
  2. CASI vs LGVN Comparison

CASI vs LGVN Comparison

Compare CASI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • LGVN
  • Stock Information
  • Founded
  • CASI 1991
  • LGVN 2014
  • Country
  • CASI China
  • LGVN United States
  • Employees
  • CASI N/A
  • LGVN 25
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • LGVN Medicinal Chemicals and Botanical Products
  • Sector
  • CASI Health Care
  • LGVN Health Care
  • Exchange
  • CASI Nasdaq
  • LGVN Nasdaq
  • Market Cap
  • CASI 31.0M
  • LGVN 23.4M
  • IPO Year
  • CASI 1996
  • LGVN 2021
  • Fundamental
  • Price
  • CASI $1.89
  • LGVN $1.34
  • Analyst Decision
  • CASI Strong Buy
  • LGVN Strong Buy
  • Analyst Count
  • CASI 1
  • LGVN 3
  • Target Price
  • CASI $4.00
  • LGVN $8.67
  • AVG Volume (30 Days)
  • CASI 8.4K
  • LGVN 122.2K
  • Earning Date
  • CASI 05-20-2025
  • LGVN 05-08-2025
  • Dividend Yield
  • CASI N/A
  • LGVN N/A
  • EPS Growth
  • CASI N/A
  • LGVN N/A
  • EPS
  • CASI N/A
  • LGVN N/A
  • Revenue
  • CASI $28,537,000.00
  • LGVN $2,392,000.00
  • Revenue This Year
  • CASI N/A
  • LGVN $1.30
  • Revenue Next Year
  • CASI N/A
  • LGVN $19.15
  • P/E Ratio
  • CASI N/A
  • LGVN N/A
  • Revenue Growth
  • CASI N/A
  • LGVN 237.38
  • 52 Week Low
  • CASI $1.64
  • LGVN $0.77
  • 52 Week High
  • CASI $7.67
  • LGVN $6.40
  • Technical
  • Relative Strength Index (RSI)
  • CASI 44.54
  • LGVN 38.24
  • Support Level
  • CASI $1.64
  • LGVN $1.48
  • Resistance Level
  • CASI $1.94
  • LGVN $1.77
  • Average True Range (ATR)
  • CASI 0.09
  • LGVN 0.13
  • MACD
  • CASI -0.00
  • LGVN -0.02
  • Stochastic Oscillator
  • CASI 55.77
  • LGVN 7.55

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Share on Social Networks: